Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angioedemas, Hereditary | 20 | 2024 | 91 | 3.470 |
Why?
|
Complement C1 Inhibitor Protein | 12 | 2022 | 97 | 2.200 |
Why?
|
Head and Neck Neoplasms | 30 | 2022 | 2931 | 1.010 |
Why?
|
Boron Neutron Capture Therapy | 7 | 2008 | 51 | 0.700 |
Why?
|
Oropharyngeal Neoplasms | 8 | 2022 | 493 | 0.680 |
Why?
|
Boron | 6 | 2008 | 37 | 0.660 |
Why?
|
Asthma | 13 | 2023 | 6293 | 0.600 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2019 | 4064 | 0.490 |
Why?
|
Boron Compounds | 5 | 2004 | 196 | 0.440 |
Why?
|
Angioedema | 2 | 2014 | 184 | 0.440 |
Why?
|
Hypersensitivity | 1 | 2020 | 1173 | 0.360 |
Why?
|
Radiotherapy, Intensity-Modulated | 6 | 2018 | 812 | 0.350 |
Why?
|
September 11 Terrorist Attacks | 2 | 2021 | 107 | 0.350 |
Why?
|
Rectal Neoplasms | 7 | 1999 | 1183 | 0.330 |
Why?
|
Nose Neoplasms | 3 | 2016 | 250 | 0.330 |
Why?
|
Carcinoma, Adenoid Cystic | 3 | 2020 | 264 | 0.310 |
Why?
|
Combined Modality Therapy | 33 | 2020 | 8559 | 0.310 |
Why?
|
Plasma Kallikrein | 2 | 2018 | 21 | 0.290 |
Why?
|
Radiotherapy Dosage | 15 | 2019 | 2921 | 0.290 |
Why?
|
Fluorouracil | 14 | 2006 | 1655 | 0.290 |
Why?
|
Leucovorin | 8 | 2004 | 643 | 0.280 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2008 | 329 | 0.280 |
Why?
|
Drugs, Chinese Herbal | 3 | 2015 | 147 | 0.260 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2019 | 290 | 0.250 |
Why?
|
Allergens | 3 | 2018 | 1444 | 0.250 |
Why?
|
Fructose | 3 | 2004 | 284 | 0.250 |
Why?
|
Taxoids | 7 | 2006 | 668 | 0.240 |
Why?
|
Registries | 4 | 2017 | 8384 | 0.240 |
Why?
|
Carcinoma | 5 | 2016 | 2340 | 0.230 |
Why?
|
Immunocompromised Host | 2 | 2016 | 863 | 0.230 |
Why?
|
Nasal Cavity | 2 | 2016 | 311 | 0.220 |
Why?
|
Cisplatin | 13 | 2015 | 1661 | 0.220 |
Why?
|
Tongue Neoplasms | 1 | 2005 | 186 | 0.210 |
Why?
|
Reishi | 2 | 2015 | 2 | 0.210 |
Why?
|
Urban Health | 1 | 2005 | 535 | 0.210 |
Why?
|
Anti-Asthmatic Agents | 3 | 2015 | 577 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2015 | 11886 | 0.200 |
Why?
|
Hypersensitivity, Immediate | 1 | 2005 | 349 | 0.200 |
Why?
|
Maximum Tolerated Dose | 2 | 2009 | 899 | 0.190 |
Why?
|
Complement Inactivating Agents | 2 | 2011 | 53 | 0.180 |
Why?
|
Skin Neoplasms | 6 | 2016 | 5864 | 0.180 |
Why?
|
Rescue Work | 1 | 2020 | 58 | 0.180 |
Why?
|
Humans | 112 | 2024 | 768970 | 0.170 |
Why?
|
Radiation-Sensitizing Agents | 5 | 1999 | 349 | 0.170 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 1126 | 0.170 |
Why?
|
Radiation Injuries | 5 | 2019 | 1203 | 0.170 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2019 | 47 | 0.170 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 6 | 2019 | 1679 | 0.170 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2023 | 4640 | 0.170 |
Why?
|
Peanut Hypersensitivity | 1 | 2002 | 219 | 0.160 |
Why?
|
Phenylalanine | 1 | 2001 | 368 | 0.160 |
Why?
|
Paclitaxel | 8 | 2009 | 1735 | 0.160 |
Why?
|
Brachytherapy | 2 | 2014 | 1224 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
Middle Aged | 58 | 2024 | 223737 | 0.160 |
Why?
|
Adult | 49 | 2024 | 223851 | 0.150 |
Why?
|
Papillomavirus Infections | 3 | 2022 | 1640 | 0.150 |
Why?
|
Glycyrrhiza uralensis | 3 | 2015 | 3 | 0.150 |
Why?
|
Antidotes | 1 | 1998 | 138 | 0.150 |
Why?
|
Paranasal Sinus Neoplasms | 2 | 2016 | 243 | 0.140 |
Why?
|
Neoplasms, Squamous Cell | 2 | 2009 | 95 | 0.140 |
Why?
|
Melanoma | 5 | 2003 | 5709 | 0.140 |
Why?
|
Male | 63 | 2024 | 365203 | 0.140 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7460 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2008 | 877 | 0.140 |
Why?
|
Quality of Life | 9 | 2024 | 13510 | 0.140 |
Why?
|
Urban Population | 1 | 2005 | 2046 | 0.140 |
Why?
|
Neoplasm Staging | 15 | 2019 | 11262 | 0.140 |
Why?
|
Female | 64 | 2024 | 397515 | 0.130 |
Why?
|
Glioblastoma | 5 | 2004 | 3525 | 0.130 |
Why?
|
Brain Neoplasms | 9 | 2019 | 9213 | 0.130 |
Why?
|
Chemoprevention | 1 | 2018 | 326 | 0.130 |
Why?
|
Rectum | 2 | 1999 | 900 | 0.130 |
Why?
|
Clinical Protocols | 2 | 2017 | 1445 | 0.130 |
Why?
|
Aged | 42 | 2024 | 171786 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
Histone Deacetylase 2 | 1 | 2015 | 72 | 0.120 |
Why?
|
Mucin 5AC | 1 | 2015 | 96 | 0.120 |
Why?
|
Triterpenes | 1 | 2015 | 78 | 0.120 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 58 | 0.120 |
Why?
|
STAT6 Transcription Factor | 1 | 2015 | 196 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1998 | 647 | 0.120 |
Why?
|
Sophora | 2 | 2015 | 3 | 0.120 |
Why?
|
Adolescent | 19 | 2024 | 89244 | 0.110 |
Why?
|
Photons | 1 | 2018 | 595 | 0.110 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2006 | 622 | 0.110 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 92 | 0.110 |
Why?
|
Skull Base | 1 | 2016 | 294 | 0.110 |
Why?
|
Caffeine | 4 | 1980 | 703 | 0.110 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4926 | 0.110 |
Why?
|
Facial Neoplasms | 1 | 2014 | 126 | 0.110 |
Why?
|
Europe | 2 | 2017 | 3441 | 0.110 |
Why?
|
Nasopharynx | 1 | 2016 | 420 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1408 | 0.100 |
Why?
|
Liver Neoplasms | 1 | 2008 | 4363 | 0.100 |
Why?
|
Carcinoma, Basal Cell | 2 | 2016 | 565 | 0.100 |
Why?
|
Child | 16 | 2018 | 80960 | 0.100 |
Why?
|
Treatment Outcome | 23 | 2024 | 65480 | 0.100 |
Why?
|
Flavonoids | 1 | 2015 | 447 | 0.100 |
Why?
|
Patients | 1 | 2018 | 908 | 0.090 |
Why?
|
Survival Analysis | 9 | 2020 | 10115 | 0.090 |
Why?
|
Premedication | 1 | 2012 | 246 | 0.090 |
Why?
|
Scalp | 1 | 2014 | 391 | 0.090 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 428 | 0.090 |
Why?
|
Disease-Free Survival | 7 | 2018 | 6856 | 0.090 |
Why?
|
Morbidity | 3 | 2023 | 1757 | 0.090 |
Why?
|
Cost of Illness | 2 | 2018 | 1960 | 0.090 |
Why?
|
Young Adult | 14 | 2024 | 60131 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2019 | 9442 | 0.090 |
Why?
|
Immunoglobulin E | 4 | 2018 | 1506 | 0.090 |
Why?
|
Neutron Capture Therapy | 2 | 2015 | 6 | 0.080 |
Why?
|
Adenocarcinoma | 7 | 1994 | 6401 | 0.080 |
Why?
|
Occupational Diseases | 1 | 2018 | 1458 | 0.080 |
Why?
|
NF-kappa B | 2 | 2015 | 2492 | 0.080 |
Why?
|
Nutrition Policy | 1 | 2013 | 467 | 0.080 |
Why?
|
Gallbladder Neoplasms | 1 | 1991 | 190 | 0.080 |
Why?
|
Esophageal Stenosis | 2 | 2013 | 197 | 0.080 |
Why?
|
Peptides | 2 | 2018 | 4353 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2016 | 1793 | 0.080 |
Why?
|
Epidemics | 1 | 2014 | 517 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1209 | 0.080 |
Why?
|
Basophils | 1 | 2010 | 407 | 0.080 |
Why?
|
Lymphatic Metastasis | 4 | 2008 | 2916 | 0.080 |
Why?
|
Human papillomavirus 16 | 1 | 2010 | 268 | 0.070 |
Why?
|
Thromboembolism | 1 | 2014 | 1004 | 0.070 |
Why?
|
Gene Expression | 2 | 2019 | 7603 | 0.070 |
Why?
|
Colonic Neoplasms | 2 | 1997 | 2543 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3726 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3492 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 1989 | 187 | 0.070 |
Why?
|
Lymphatic Diseases | 2 | 2008 | 319 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1944 | 0.070 |
Why?
|
Phytotherapy | 1 | 2009 | 298 | 0.070 |
Why?
|
Plant Extracts | 1 | 2010 | 499 | 0.070 |
Why?
|
Medical Oncology | 2 | 2020 | 2350 | 0.070 |
Why?
|
Actuarial Analysis | 2 | 2019 | 372 | 0.070 |
Why?
|
Recurrence | 4 | 2020 | 8513 | 0.070 |
Why?
|
Double-Blind Method | 5 | 2024 | 12467 | 0.070 |
Why?
|
Guidelines as Topic | 3 | 2018 | 1399 | 0.070 |
Why?
|
United States | 12 | 2020 | 73186 | 0.070 |
Why?
|
Aged, 80 and over | 13 | 2019 | 59739 | 0.070 |
Why?
|
Infusions, Intravenous | 5 | 2010 | 2231 | 0.070 |
Why?
|
New York City | 2 | 2020 | 737 | 0.070 |
Why?
|
HIV Infections | 2 | 2014 | 17591 | 0.070 |
Why?
|
Cystadenocarcinoma | 1 | 2005 | 54 | 0.060 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9264 | 0.060 |
Why?
|
Iridium Radioisotopes | 1 | 2005 | 26 | 0.060 |
Why?
|
Tonsillar Neoplasms | 1 | 2005 | 50 | 0.060 |
Why?
|
Emergency Service, Hospital | 2 | 2016 | 7957 | 0.060 |
Why?
|
Mice | 6 | 2018 | 82072 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2015 | 4356 | 0.060 |
Why?
|
Child, Preschool | 9 | 2018 | 42683 | 0.060 |
Why?
|
Complement C1 Inactivator Proteins | 2 | 2016 | 89 | 0.060 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2005 | 90 | 0.060 |
Why?
|
Societies, Medical | 4 | 2019 | 3968 | 0.060 |
Why?
|
Models, Biological | 1 | 2001 | 9499 | 0.060 |
Why?
|
Hematologic Tests | 1 | 2005 | 239 | 0.060 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2018 | 827 | 0.060 |
Why?
|
Antifibrinolytic Agents | 2 | 2018 | 289 | 0.060 |
Why?
|
Family | 1 | 2015 | 3208 | 0.060 |
Why?
|
Carboplatin | 4 | 2009 | 799 | 0.060 |
Why?
|
Remission Induction | 5 | 2009 | 2408 | 0.050 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10276 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2008 | 1836 | 0.050 |
Why?
|
Mast Cells | 1 | 2010 | 1406 | 0.050 |
Why?
|
Skin Tests | 1 | 2005 | 639 | 0.050 |
Why?
|
Prognosis | 8 | 2019 | 30046 | 0.050 |
Why?
|
Depressive Disorder, Major | 1 | 2020 | 4818 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2008 | 904 | 0.050 |
Why?
|
Food Hypersensitivity | 1 | 2010 | 734 | 0.050 |
Why?
|
Factor XIIa | 1 | 2022 | 14 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2017 | 10765 | 0.050 |
Why?
|
Head | 1 | 2008 | 927 | 0.050 |
Why?
|
Intraoperative Care | 2 | 1999 | 771 | 0.050 |
Why?
|
Radiation Injuries, Experimental | 1 | 2002 | 88 | 0.050 |
Why?
|
Esterases | 1 | 2022 | 89 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 6214 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 1 | 2008 | 2598 | 0.050 |
Why?
|
Half-Life | 1 | 2003 | 651 | 0.050 |
Why?
|
Interphase | 2 | 1980 | 227 | 0.050 |
Why?
|
Laryngeal Neoplasms | 1 | 2005 | 514 | 0.050 |
Why?
|
Developing Countries | 1 | 2014 | 2911 | 0.050 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2005 | 526 | 0.050 |
Why?
|
Brain | 4 | 2019 | 27453 | 0.050 |
Why?
|
Patient Education as Topic | 2 | 2016 | 2339 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 13021 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3709 | 0.050 |
Why?
|
Quality Improvement | 1 | 2016 | 3860 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10400 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2005 | 3554 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 2 | 2015 | 761 | 0.040 |
Why?
|
HeLa Cells | 4 | 1980 | 3076 | 0.040 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39394 | 0.040 |
Why?
|
Fluorine Radioisotopes | 1 | 2003 | 424 | 0.040 |
Why?
|
Disease Progression | 5 | 2018 | 13674 | 0.040 |
Why?
|
Stomatitis | 1 | 2002 | 271 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2008 | 1903 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2018 | 640 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2002 | 437 | 0.040 |
Why?
|
Lung | 3 | 2010 | 10099 | 0.040 |
Why?
|
Neoplasm Invasiveness | 3 | 2016 | 3629 | 0.040 |
Why?
|
Intraoperative Period | 2 | 1991 | 513 | 0.040 |
Why?
|
Patient Compliance | 2 | 2009 | 2701 | 0.040 |
Why?
|
Animal Technicians | 1 | 2018 | 7 | 0.040 |
Why?
|
Aging | 1 | 2017 | 8745 | 0.040 |
Why?
|
Animals, Laboratory | 1 | 2018 | 46 | 0.040 |
Why?
|
Air Pollution, Indoor | 1 | 2005 | 931 | 0.040 |
Why?
|
X-Rays | 4 | 1980 | 311 | 0.040 |
Why?
|
Apoptosis | 2 | 2015 | 9527 | 0.040 |
Why?
|
Perineum | 1 | 1999 | 212 | 0.040 |
Why?
|
Interleukin-5 | 1 | 2018 | 267 | 0.040 |
Why?
|
Epitope Mapping | 1 | 2018 | 300 | 0.030 |
Why?
|
Immunodominant Epitopes | 1 | 2018 | 244 | 0.030 |
Why?
|
Danazol | 1 | 2016 | 44 | 0.030 |
Why?
|
Radiometry | 1 | 2002 | 817 | 0.030 |
Why?
|
Texas | 1 | 2018 | 410 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12562 | 0.030 |
Why?
|
Preoperative Care | 2 | 1998 | 2258 | 0.030 |
Why?
|
Methods | 1 | 1997 | 1066 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2001 | 667 | 0.030 |
Why?
|
Pharyngectomy | 1 | 2016 | 45 | 0.030 |
Why?
|
Bradykinin | 1 | 2016 | 205 | 0.030 |
Why?
|
Infant | 4 | 2018 | 36556 | 0.030 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 325 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 167 | 0.030 |
Why?
|
Organs at Risk | 1 | 2018 | 368 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2022 | 1140 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 2016 | 115 | 0.030 |
Why?
|
Acute Disease | 3 | 2011 | 7245 | 0.030 |
Why?
|
Oropharynx | 1 | 2016 | 139 | 0.030 |
Why?
|
Radiotherapy | 3 | 2010 | 1506 | 0.030 |
Why?
|
Cell Survival | 3 | 1980 | 5793 | 0.030 |
Why?
|
Neoplasms | 2 | 2014 | 22389 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 594 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1620 | 0.030 |
Why?
|
Survival Rate | 4 | 2016 | 12873 | 0.030 |
Why?
|
Disease Management | 2 | 2016 | 2537 | 0.030 |
Why?
|
Topotecan | 1 | 2015 | 131 | 0.030 |
Why?
|
Neck Dissection | 1 | 2016 | 201 | 0.030 |
Why?
|
Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15661 | 0.030 |
Why?
|
Forefoot, Human | 1 | 2014 | 31 | 0.030 |
Why?
|
Phantoms, Imaging | 2 | 2002 | 2533 | 0.030 |
Why?
|
Relative Biological Effectiveness | 1 | 2016 | 313 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6332 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2015 | 466 | 0.030 |
Why?
|
Retrospective Studies | 8 | 2019 | 81903 | 0.030 |
Why?
|
Probability | 1 | 2019 | 2483 | 0.030 |
Why?
|
Tranexamic Acid | 1 | 2016 | 174 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 468 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2002 | 3810 | 0.030 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13698 | 0.030 |
Why?
|
Mice, Inbred BALB C | 2 | 2015 | 6232 | 0.030 |
Why?
|
Terrorism | 1 | 2016 | 211 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2009 | 5342 | 0.030 |
Why?
|
Dust | 1 | 2016 | 488 | 0.030 |
Why?
|
Prospective Studies | 5 | 2021 | 54962 | 0.030 |
Why?
|
Transcription Factor AP-1 | 1 | 2015 | 321 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 639 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2014 | 236 | 0.030 |
Why?
|
Mucus | 1 | 2015 | 346 | 0.030 |
Why?
|
Xerostomia | 1 | 2013 | 94 | 0.030 |
Why?
|
Abdomen | 1 | 1999 | 1137 | 0.030 |
Why?
|
Denmark | 1 | 2015 | 776 | 0.030 |
Why?
|
Vincristine | 1 | 2015 | 1040 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2001 | 1273 | 0.030 |
Why?
|
Risk Assessment | 3 | 2020 | 24333 | 0.020 |
Why?
|
Delphi Technique | 1 | 2016 | 890 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 1997 | 1019 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2009 | 20776 | 0.020 |
Why?
|
History, 21st Century | 1 | 2018 | 1575 | 0.020 |
Why?
|
Complement System Proteins | 1 | 2015 | 738 | 0.020 |
Why?
|
Capacity Building | 1 | 2014 | 265 | 0.020 |
Why?
|
Carbon | 1 | 2015 | 672 | 0.020 |
Why?
|
Molecular Structure | 2 | 2010 | 1885 | 0.020 |
Why?
|
Botswana | 1 | 2014 | 1065 | 0.020 |
Why?
|
Filtration | 1 | 2011 | 228 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15604 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2003 | 3580 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2014 | 433 | 0.020 |
Why?
|
Animals | 8 | 2018 | 169335 | 0.020 |
Why?
|
Androgens | 1 | 2018 | 1285 | 0.020 |
Why?
|
Airway Management | 1 | 2014 | 326 | 0.020 |
Why?
|
Gastrostomy | 1 | 2013 | 325 | 0.020 |
Why?
|
Ultrafiltration | 1 | 2010 | 48 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5891 | 0.020 |
Why?
|
Cell Cycle | 1 | 1978 | 2937 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2015 | 1246 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 41808 | 0.020 |
Why?
|
Administration, Oral | 1 | 2018 | 4040 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2005 | 4544 | 0.020 |
Why?
|
Leukotriene C4 | 1 | 2010 | 79 | 0.020 |
Why?
|
Surgical Flaps | 1 | 1999 | 1682 | 0.020 |
Why?
|
Advisory Committees | 1 | 2014 | 797 | 0.020 |
Why?
|
Cell Degranulation | 1 | 2010 | 277 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 2010 | 915 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2018 | 3163 | 0.020 |
Why?
|
Prostaglandins | 1 | 2010 | 398 | 0.020 |
Why?
|
Airway Remodeling | 1 | 2010 | 133 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2227 | 0.020 |
Why?
|
Receptors, IgE | 1 | 2010 | 375 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1281 | 0.020 |
Why?
|
Plant Roots | 1 | 2009 | 122 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2014 | 677 | 0.020 |
Why?
|
Histamine | 1 | 2010 | 496 | 0.020 |
Why?
|
Anal Canal | 1 | 1991 | 376 | 0.020 |
Why?
|
Isotopes | 1 | 2008 | 125 | 0.020 |
Why?
|
Ovalbumin | 1 | 2010 | 677 | 0.020 |
Why?
|
Treatment Failure | 3 | 2003 | 2664 | 0.020 |
Why?
|
Survival | 1 | 2008 | 160 | 0.020 |
Why?
|
Cholangitis | 1 | 1989 | 110 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1994 | 716 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2234 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 1855 | 0.020 |
Why?
|
Metabolomics | 1 | 2017 | 1675 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2010 | 6236 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1672 | 0.020 |
Why?
|
Proteome | 1 | 2018 | 1891 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2014 | 849 | 0.020 |
Why?
|
DNA | 2 | 1980 | 7214 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3813 | 0.020 |
Why?
|
bcl-X Protein | 1 | 2009 | 412 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2015 | 10486 | 0.020 |
Why?
|
Rats, Inbred F344 | 1 | 2008 | 825 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1515 | 0.020 |
Why?
|
Enteral Nutrition | 1 | 2013 | 802 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2013 | 641 | 0.020 |
Why?
|
Time Factors | 5 | 2013 | 40261 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2018 | 26428 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6512 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1818 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1629 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2276 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 1833 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2010 | 1536 | 0.020 |
Why?
|
Eating | 1 | 2013 | 1542 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 15471 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2016 | 1807 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2182 | 0.020 |
Why?
|
Mental Health | 1 | 2020 | 3275 | 0.020 |
Why?
|
Fear | 1 | 2015 | 1493 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2010 | 703 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 1705 | 0.020 |
Why?
|
Contrast Media | 1 | 2019 | 5334 | 0.020 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1258 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11116 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 2009 | 740 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21547 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2015 | 2434 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2014 | 2203 | 0.020 |
Why?
|
Physical Examination | 2 | 2009 | 1262 | 0.020 |
Why?
|
Drug Administration Schedule | 3 | 2003 | 4862 | 0.020 |
Why?
|
Eosinophils | 1 | 2010 | 953 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2528 | 0.020 |
Why?
|
Fast Neutrons | 1 | 2004 | 18 | 0.020 |
Why?
|
Risk Factors | 2 | 2023 | 74976 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2016 | 1947 | 0.010 |
Why?
|
Nanotechnology | 1 | 2010 | 714 | 0.010 |
Why?
|
Cytokines | 2 | 2010 | 7453 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6547 | 0.010 |
Why?
|
Proteomics | 1 | 2018 | 3914 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14794 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6346 | 0.010 |
Why?
|
Trachea | 1 | 2010 | 1095 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2108 | 0.010 |
Why?
|
Esophageal Neoplasms | 1 | 1994 | 1674 | 0.010 |
Why?
|
Salvage Therapy | 2 | 2005 | 1277 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 1999 | 4978 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2010 | 17173 | 0.010 |
Why?
|
Laryngectomy | 1 | 2005 | 245 | 0.010 |
Why?
|
Anaphylaxis | 1 | 2010 | 758 | 0.010 |
Why?
|
Genetic Testing | 1 | 2016 | 3591 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2666 | 0.010 |
Why?
|
Rats | 2 | 2010 | 23786 | 0.010 |
Why?
|
DNA, Viral | 1 | 2010 | 2205 | 0.010 |
Why?
|
Tumor Burden | 1 | 2009 | 1913 | 0.010 |
Why?
|
Proteins | 1 | 2018 | 6011 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2018 | 4339 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2015 | 3702 | 0.010 |
Why?
|
Mesocricetus | 1 | 2002 | 256 | 0.010 |
Why?
|
DNA Polymerase III | 1 | 2002 | 52 | 0.010 |
Why?
|
Neutrons | 1 | 2002 | 78 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2044 | 0.010 |
Why?
|
Respiration | 1 | 2008 | 1668 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2016 | 3238 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8894 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9377 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2003 | 330 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2009 | 6131 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2009 | 15951 | 0.010 |
Why?
|
Health Care Costs | 1 | 2014 | 3270 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2002 | 515 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3269 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2015 | 18354 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2056 | 0.010 |
Why?
|
Macrophages | 1 | 2015 | 5801 | 0.010 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2002 | 395 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2003 | 631 | 0.010 |
Why?
|
Deuterium Oxide | 1 | 1999 | 34 | 0.010 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2002 | 423 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19023 | 0.010 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 911 | 0.010 |
Why?
|
Pilot Projects | 2 | 1991 | 8748 | 0.010 |
Why?
|
Floxuridine | 1 | 1978 | 44 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2004 | 1262 | 0.010 |
Why?
|
Pelvic Exenteration | 1 | 1999 | 22 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2734 | 0.010 |
Why?
|
Smoking | 1 | 2016 | 9094 | 0.010 |
Why?
|
Cricetinae | 1 | 2002 | 2423 | 0.010 |
Why?
|
Fibroblasts | 1 | 2009 | 4179 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2003 | 13594 | 0.010 |
Why?
|
Thyrotropin | 1 | 2001 | 834 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15879 | 0.010 |
Why?
|
Solubility | 1 | 1999 | 1087 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5522 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11932 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23653 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 1997 | 21188 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 1993 | 5443 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1999 | 2298 | 0.010 |
Why?
|
Chronic Disease | 1 | 1989 | 9384 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10847 | 0.010 |
Why?
|
Suture Techniques | 1 | 1999 | 779 | 0.010 |
Why?
|
Tamoxifen | 1 | 1997 | 967 | 0.010 |
Why?
|
Water | 1 | 1999 | 1421 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6673 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2002 | 2960 | 0.010 |
Why?
|
Laparotomy | 1 | 1993 | 459 | 0.010 |
Why?
|
Cell Division | 1 | 1977 | 4478 | 0.010 |
Why?
|
Tetrahydrofolates | 1 | 1990 | 58 | 0.010 |
Why?
|
Pancreaticoduodenectomy | 1 | 1993 | 516 | 0.010 |
Why?
|
Odds Ratio | 1 | 2001 | 9684 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 1535 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1999 | 3782 | 0.000 |
Why?
|
Drug Evaluation | 1 | 1990 | 642 | 0.000 |
Why?
|
Pancreatectomy | 1 | 1993 | 825 | 0.000 |
Why?
|
Palpation | 1 | 1985 | 166 | 0.000 |
Why?
|
Radiation Dosage | 1 | 1993 | 1970 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1999 | 15889 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 1999 | 36854 | 0.000 |
Why?
|